<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We have performed an allogeneic stem cell transplant in an 18-year-old male patient who had Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The patient had disease which was refractory to conventional intensive chemotherapy and radiation therapy </plain></SENT>
<SENT sid="2" pm="."><plain>High-dose chemotherapy with autologous stem cell rescue was given but the patient relapsed within 2 months after transplantation </plain></SENT>
<SENT sid="3" pm="."><plain>He was then treated with allogeneic stem cell transplantation using a fludarabine, <z:chebi fb="0" ids="28901">busulfan</z:chebi> and anti-thymocyte globulin-based conditioning regimen </plain></SENT>
<SENT sid="4" pm="."><plain>His GVHD prophylaxis included <z:chebi fb="0" ids="168396">mycophenolate</z:chebi> and tacrolimus </plain></SENT>
<SENT sid="5" pm="."><plain>The patient had engraftment within 14 days </plain></SENT>
<SENT sid="6" pm="."><plain>Investigation by FISH showed more than 95% of his peripheral blood nucleated cells to be of donor origin since day +14 </plain></SENT>
<SENT sid="7" pm="."><plain>He is now alive and well and remains disease-free 6-months after the transplant </plain></SENT>
<SENT sid="8" pm="."><plain>A graft-versus-<z:hpo ids='HP_0002665'>lymphoma</z:hpo> effect is thought to be one of the factors contributing to his remission </plain></SENT>
</text></document>